Skip to Content
Regeneron Pharmaceuticals Inc. Logo.

Press Releases

October 1, 2026 11:35 AM EDT

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Read press release : Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

October 1, 2026 11:30 AM EDT

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Read press release : Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

October 1, 2026 1:00 AM EDT

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Read press release : Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

September 24, 2026 4:05 PM EDT

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

Read press release : Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

August 19, 2026 4:05 PM EDT

Regeneron Announces Investor Conference Presentations

Read press release : Regeneron Announces Investor Conference Presentations

August 19, 2026 1:58 PM EDT

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Read press release : Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

July 31, 2026 7:00 AM EDT

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Read press release : Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

July 30, 2026 6:30 AM EDT

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Read press release : Regeneron Reports Second Quarter 2026 Financial and Operating Results

June 25, 2026 4:05 PM EDT

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Read press release : Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

June 22, 2026 7:00 AM EDT

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Read press release : Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
Back to top